Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Long-term outcomes of IL-2R antibody vs antithymocyte globulin for induction therapy in kidney transplantation

Nature Clinical Practice Nephrology volume 3, pages 134–135 (2007)Cite this article

boxed-textBeaudreuil S et al. (2006) Long-term results (10 years) of a prospective trial comparing Lo-tact-1 monoclonal antibody and anti-thymocyte globulin induction therapy in kidney transplantation. Transplant Int 19: 814–820

It has not yet been established which immunosuppressive regimen (including which antibody induction therapy) optimizes the long-term survival of a kidney transplant

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ciancio G et al. (2005) A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 80: 457–465

    Article  CAS  Google Scholar 

  2. Lebranchu Y et al. (2002) Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2: 48–56

    Article  CAS  Google Scholar 

  3. Schulz T et al. (2005) Neoquadruple induction with antithymocyte globulin/azathioprine/cyclosporine/prednisolone in simultaneous pancreas and kidney transplant recipients: 8.5-year results. Transplant Proc 37: 1815–1817

    Article  CAS  Google Scholar 

  4. Wabbijn M et al. (2004) Ten-year follow-up of recipients of a kidney or heart transplant who received induction therapy with a monoclonal antibody against the interleukin-2 receptor. Exp Clin Transplant 2: 201–207

    PubMed  Google Scholar 

  5. Nankivell BJ et al. (2003) The natural history of chronic allograft nephropathy. N Engl J Med 349: 2326–2333

    Article  CAS  Google Scholar 

  6. Choi BS et al. (2005) Clinical significance of an early protocol biopsy in living-donor renal transplantation: ten-year experience at a single center. Am J Transplant 5: 1354–1360

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Chloë Harman, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. GW Burke and G Ciancio are Professors of Surgery at the University of Miami Miller School of Medicine, Miami, FL, USA.,

    George W Burke III & Gaetano Ciancio

Authors
  1. George W Burke III
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gaetano Ciancio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George W Burke III.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Burke, G., Ciancio, G. Long-term outcomes of IL-2R antibody vs antithymocyte globulin for induction therapy in kidney transplantation. Nat Rev Nephrol 3, 134–135 (2007). https://doi.org/10.1038/ncpneph0393

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneph0393

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing